In partnership with
MDMA THERAPY GOT ALL THE WAY TO THE FDA
MDMA Nearly Became A Prescription Medicine In America
The FDA Had Never Reviewed A Treatment Like It
Trials Ran For Years Under An Agreed Protocol
Results Looked Strong Enough To Reach The Final Stage
Regulators Rejected The Application In 2024
The Reasons Had Little To Do With The Molecule
This Final Part Covers How That Happened
THIS NEWSLETTER IS FOR INFORMATIONAL PURPOSES ONLY. NOTHING IN THIS CONTENT CONSTITUTES MEDICAL, PSYCHOLOGICAL, OR PROFESSIONAL ADVICE. ALWAYS CONSULT A QUALIFIED HEALTHCARE PROFESSIONAL BEFORE MAKING ANY HEALTH RELATED DECISIONS
A Quick Shoutout To Our Sponsor: TLDR.TECH
Here's What They Have For You 👾
👇🏻
Keep up with tech in 5 minutes
TLDR is the free daily email with summaries of the most interesting stories in startups, tech, and programming. The stuff worth knowing, minus the doomscrolling.
Issues are curated by ex-Google and Anthropic engineers and land in your inbox before your morning coffee. A 5-minute read, and you walk into the day already knowing what your team is still catching up on.
Tech is just the start. We also cover AI, marketing, dev, and more. Pick the briefs that match your work.
Free, daily, and read by 7M+ subscribers. Subscribe and let the experts do the digging for the tech news that matters.
OKAY BACK FROM THE HEARING ROOM 🏛️
👇🏻
THE TRIALS 🧪
Researchers Studied MDMA For Post Traumatic Stress Disorder
The Model Paired Doses With Structured Therapy Sessions
Patients Received The Drug A Small Number Of Times
Therapists Remained Present Throughout Each Session
Regulators Granted Breakthrough Therapy Designation
That Status Signals Promise And Speeds Review
Two Phase Three Trials Were Completed
Published Results Reported Large Reductions In Symptoms
Many Participants No Longer Met The Diagnostic Criteria
Advocates Described The Findings As Historic
A Company Called Lykos Therapeutics Filed For Approval
The Application Reached The Food And Drug Administration
Supporters Expected Clearance Within The Year
Veterans Groups Publicly Backed The Effort
Legislators From Both Parties Expressed Support
Reversal Appeared Unlikely At That Point
Independent Reviewers Then Examined The Evidence
Their Conclusions Went The Other Way
A Quick Shoutout To Our Sponsor: KALSHI
Here's What They Have For You 💰
👇🏻
Put Your Predictions to Work
Trade on real-world events you already follow, from elections and inflation to sports, tech, and more. Choose “Yes” or “No” based on what you think will happen and see how your prediction plays out.
Pick your market and start trading what’s next.
Bonus credit varies from $15 to $500. Terms apply.
THE TWO VOTES 🗳️
An Advisory Committee Met In June 2024
Members Reviewed The Trial Data In Public
The First Vote Asked Whether The Treatment Worked
Nine Members Said No And Two Said Yes
A Second Vote Weighed Benefits Against Risks
Ten Said The Risks Were Not Justified
One Member Disagreed
Those Numbers Ended The Expected Approval
The Agency Issued Its Decision On August 9
A Complete Response Letter Explained The Refusal
Regulators Said The Data Could Not Support Approval
They Requested An Additional Phase Three Trial
The Central Objection Involved Blinding
Participants Could Tell Whether They Received MDMA
At Least 90 Percent Guessed Correctly
That Knowledge Shapes How People Report Symptoms
Allegations About Therapist Conduct Also Reached Reviewers
Questions About Data Integrity Followed
A Quick Shoutout To Our Sponsor: FORWARD FUTURE
Here's What They Have For You ⚡️
👇🏻
Wake Up Smarter About AI.
Most people feel behind. But the people that don’t, aren’t smarter. They’re just better informed.
The Future Today is a daily news briefing for people who want clarity.
In one concise newsletter, you’ll get the most important tech news, learn why it matters, and what it signals about what’s coming next.
One email. Five Minutes. Stay ahead of 99% of the world.
WHERE IT STANDS 🚪
MDMA Remains A Schedule One Substance
No Approved Medical Use Exists In America
Australia Made A Different Call In 2023
Psychiatrists There Can Prescribe It For PTSD
The American Rejection Did Not Rule The Treatment Out
Regulators Asked For Better Evidence Rather Than None
The Complete Response Letter Became Public In 2025
Companies Testing Similar Drugs Adjusted Their Designs
Blinding Remains The Hardest Problem To Solve
A Drug With Obvious Effects Resists Placebo Comparison
Standard Trial Methods Were Built For Different Medicines
Veterans With Treatment Resistant Symptoms Continue Waiting
Existing Options Fail A Substantial Number Of Them
The Underlying Question Was Never Fully Answered
Nobody Established Whether The Therapy Works
These Trials Could Not Prove It Either Way
MDMA Came Closer Than Any Comparable Drug
It Still Ended Outside The American Pharmacy
The Molecule Never Changed
A 1912 Intermediate Became A Party Drug
Then A Banned Substance
Later A Clinical Trial
Almost Everyone Who Handled It Called It The Wrong Thing
